Study group | Female (%) | Median age (min to max, years) | Preoperative median BCVA (min to max, logMAR) | Axial length (mean ± SD, mm) | Postoperative follow-up months (median, range) |
Control emmetropic group (n = 25) | 76 | 52 (22 to 66) | 0.00 (−0.12 to 0.09) | 20.53 ± 0.09 | - |
Control myopic group (n = 20) | 70 | 60 (48 to 70) | 0.00 (0.00 to 0.09) | 29.45 ± 1.49 | - |
Surgical treatment group (N=46) |
|
|
|
|
|
Stage 1 (n = 5) | 84.6 | 59 (44 to 70) | 0.69 (0.60 to 1.00) | 30.54 ± 1.51 | 13 (6 - 58) |
Stage 2 (n = 26) | 75.4 | 59 (43 to 76) | 1.00 (0.60 To 1.30) | 29.38 ± 1.64 | 27 (6 - 67) |
Stage 3 (n = 4) | 90 | 61 (46 to 70) | 1.15 (0.54 to 1.30) | 30.10 ± 1.33 | 15.50 (6 - 62) |
Stage 4 (n = 11) | 71.4 | 58 (43 to 82) | 1.30 (0.60 to 1.30) | 29.94 ± 1.71 | 40 (6 - 67) |